| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97d662812918a71f262a69eec4093b93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90bf0203e25bbe6bafa73448987b5011 |
| publicationDate |
2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2720509-C2 |
| titleOfInvention |
Combined therapy pac-1 |
| abstract |
FIELD: medicine.SUBSTANCE: invention proposes combinations and methods for inducing cancer cell death. Combinations and methods for using them include using combinations for therapy in order to treat cancer and for selective induction of apoptosis in cancer cells. Combination comprises compound PAC-1 (2-(4-benzylpiperazin-1-yl)-N-[(2-hydroxy-3-prop-2-enyl-phenyl)methylideneamino]acetamide) in concentration of 4 mcM to 12 mcM and a second active ingredient which is a BRAF enzyme inhibitor having a mutation which is vemurafenib. Concentration of vemurafenib ranges from 0.5 mcM to 30 mcM. Combination also contains a pharmaceutically acceptable diluent, a filler or a carrier.EFFECT: combination of PAC-1 and vemurafenib shows synergistic anticancer activity and has less neurotoxic effects than the same amounts of other compounds and combinations of compounds, and can be effective in a specific cancer disease that has acquired resistance to previously used therapies.22 cl, 13 dwg, 1 tbl, 3 ex |
| priorityDate |
2015-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |